Table 1. Clinical features of the patients of BPDCN.

No	Age/ Sex	Neoplastic cell involvement at the time of diagnosis	G-band	Treatment	Outcome & neoplastic cell involvement at the end stage
1	73/ M	Skin, BM (Minimal involvement)	Skin sample: 96,XXYY,i(1)(q10),+8,+8,+8,+8,inc(4)	Hyper CVAD/MA	Dead, 38 months Skin, BM, LN, PB, cerebrum, cerebellum
2	83/ M	Skin, BM (Leukemic), LN, PB, spleen	BM sample: 45,X,-Y,add(6)(q21),add(9)(q22?), add(17)(q11.2)[12]/46,XY[4]	Supportive therapy	Dead, 5 months Skin, BM, LN, PB
3	73/ M	Skin, BM (Leukemic), LN, PB	BM sample: 46,XY,add(11)(q13),?der(20)t(11;20)(q13;q11.2)[9]/45-46,XY,add(11)(q13), ?der(20)t(11;20)(q13;q11.2)[cp4]/46,XY	Hyper CVAD/MA Radiation therapy to the head lesion of skin	Dead, 15 months Autopsy; Skin, BM, LN, PB, heart, lung, liver, spleen, kidney, pancreas, adrenal gland, thyroid gland, testis, esophagus, urinary bladder, peritoneum
4	37/ M	Skin, BM (Minimal involvement), PB	BM sample: Normal karyotype	Hyper CVAD/MA Allo-HSCT	Alive, 34 months (on follow-up)
5	35/ M	Skin, BM (Minimal involvement)	BM sample: Normal karyotype	Hyper CVAD/MA Auto-PBSCT	Alive, 75 months (The follow-up was ended at this time due to the patient’s opinion)
6	74/ M	Skin, BM (Leukemic), PB	ND	CHOP	Alive, 4 months (on follow up)

M, male; BM, bone marrow; LN, lymph node; PB, peripheral blood; CVAD, cyclophosphamide, doxorubicin, vincristine and dexamethasone; MA, methotrexate and cytarabine; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; Auto-PBSCT, autologous peripheral blood stem cell transplantation; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisolone, ND; no data.